News | July 30, 2025
Ajanta Pharma reports Q1 FY26 consolidated PAT at Rs. 255.34 Cr
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
